BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 31850815)

  • 1. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt.
    Seemann L; Padala SA; Mohammed A; Belayneh N
    J Investig Med High Impact Case Rep; 2019; 7():2324709619895162. PubMed ID: 31850815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
    Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
    BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed?
    Ledford CK; Zelenski NA; Cardona DM; Brigman BE; Eward WC
    Clin Orthop Relat Res; 2013 Nov; 471(11):3618-25. PubMed ID: 23868423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteomalacia-Inducing Tumors of the Brain: A Case Report, Review and a Hypothesis.
    Fathalla H; Cusimano M; Di Ieva A; Karamchandani J; Fung R; Kovacs K
    World Neurosurg; 2015 Jul; 84(1):189.e1-5. PubMed ID: 25746588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.
    Hu FK; Yuan F; Jiang CY; Lv DW; Mao BB; Zhang Q; Yuan ZQ; Wang Y
    Chin J Cancer; 2011 Nov; 30(11):794-804. PubMed ID: 22035861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-induced osteomalacia: experience from a South American academic center.
    González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
    Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
    Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
    BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occult phosphaturic mesenchymal tumour of femur cortex causing oncogenic osteomalacia - diagnostic challenges and clinical outcomes.
    Dutta D; Pandey RK; Gogoi R; Solanki N; Madan R; Mondal A; Dogra S; Thapa P
    Endokrynol Pol; 2018; 69(2):205-210. PubMed ID: 29442350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-induced osteomalacia: the long road to diagnosis and recovery.
    Vollmer S; Olsson K
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38697682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
    Seijas R; Ares O; Sierra J; Pérez-Dominguez M
    Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rickets/Osteomalacia. Diagnosis of tumor-induced osteomalacia.].
    Koga M; Ito N
    Clin Calcium; 2018; 28(10):1351-1357. PubMed ID: 30269117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
    Hannan FM; Athanasou NA; Teh J; Gibbons CL; Shine B; Thakker RV
    Eur J Endocrinol; 2008 Feb; 158(2):265-71. PubMed ID: 18230836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.
    Horng JC; Van Eperen E; Tutton S; Singh R; Shaker JL; Wooldridge AN
    Osteoporos Int; 2021 Sep; 32(9):1895-1898. PubMed ID: 33655402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-induced osteomalacia combined with increased bone resorption postoperatively: A case report.
    Shi L; Tang M; Duan S; Deng F; Zhang Y; Yang J; Hu J
    Medicine (Baltimore); 2023 Jul; 102(27):e34217. PubMed ID: 37417620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteomalacia due to phosphate deficiency caused by a tumor. Focus on FGF23 in physiology and clinic].
    Westerberg PA; Linde T; Ljunggren O
    Lakartidningen; 2012 Aug 8-21; 109(32-33):1414-6. PubMed ID: 22953430
    [No Abstract]   [Full Text] [Related]  

  • 16. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
    Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
    J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Right Leg that Troubled the Left Leg.
    B S; V A
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma.
    Slot-Steenks MM; Hamdy NA; van de Sande MA; Vriens D; Cleven AH; Appelman-Dijkstra NM
    Endocrine; 2016 Dec; 54(3):642-647. PubMed ID: 27709474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in the management of tumor-induced osteomalacia (TIO).
    Brandi ML; Clunie GPR; Houillier P; Jan de Beur SM; Minisola S; Oheim R; Seefried L
    Bone; 2021 Nov; 152():116064. PubMed ID: 34147708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Osteomalacia From a Primary Phosphaturic Mesenchymal Tumor of the Toe: A Case Report.
    Kim I; Rajani R
    J Foot Ankle Surg; 2016; 55(2):294-8. PubMed ID: 25441266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.